RecruitingPhase 2NCT06854224

Orexin Antagonism for Suicide Risk: A Proof-of-Concept Clinical Trial

Studying Mal de débarquement

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Marianne Goodman
Intervention
Suvorexant (dual orexin receptor antagonist)(drug)
Enrollment
30 target
Eligibility
18-70 years · All sexes
Timeline
20252027

Study locations (1)

Collaborators

James J. Peters Veterans Affairs Medical Center

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06854224 on ClinicalTrials.gov

Other trials for Mal de débarquement

Additional recruiting or active studies for the same condition.

See all trials for Mal de débarquement

← Back to all trials